MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Johnson & Johnson reportedly wants to sell its Cerenovus stroke business for $1B

Johnson & Johnson reportedly wants to sell its Cerenovus stroke business for $1B

By

Wire mesh that has captured a blood clot
A blood clot captured by the Cerenovus Embotrap stent retriever, which uses nitinol to expand inside a stroke patient’s blood vessels. [Image courtesy of Johnson & Johnson MedTech]
Johnson & Johnson (NYSE: JNJ) is looking to sell its Cerenovus stroke care business, according to the Financial Times, which cited three unnamed people “with knowledge of the plan.”

Those sources said New Brunswick, New Jersey–based J&J “has approached potential private equity and strategic buyers via advisers to test interest in Cerenovus.”

Two unnamed sources put the potential valuation between $1 billion and $1.5 billion.

“We do not comment on market rumors or speculation,” J&J said in a statement to MassDevice.

J&J’s Johnson & Johnson MedTech business is the world’s second-largest medical device manufacturer as ranked by the Medical Design & Outsourcing Medtech Big 100.

J&J formed Cerenovus in 2017 by combining its Pulsar Vascular and Neuravi acquisitions with what remained from its Codman Neuro neurological portfolio after its $1 billion divestiture. J&J named the neurovascular business after the Latin words for “brain” and “new.”

J&J’s neurovascular business is now headquartered in Irvine, California, and led by Worldwide President Mark Dickinson.

Medical Design & Outsourcing: Cerenovus President Mark Dickinson on the future of stroke care

J&J rebranded its iconic logo in 2023 and last year deemphasized the Cerenovus brand name along with Ethicon, DePuy Synthes, Biosense Webster and Abiomed, unifying them all as Johnson & Johnson MedTech.

Also last year, J&J bought Shockwave Medical for $13.1 billion, making it the biggest medtech deal of 2024.

Free MDO webinar: Nitinol Knowledge with Former Edwards Lifesciences Engineering SVP Ming Wu

More recent news

About Jim Hammerand

Jim Hammerand is the managing editor of Arrowfly's MassDevice and Medical Design & Outsourcing, where he leads coverage of medtech innovation, design, engineering and manufacturing. He also contributes to our Devicetalks podcasts and live events. Hammerand has more than two decades of journalism experience spanning newspapers, magazines, websites, live events, radio and TV news. For nearly a decade, Hammerand reported and edited business news for American City Business Journals as a reporter and digital editor at the Minneapolis/St. Paul Business Journal and then as managing editor of the Puget Sound Business Journal in Seattle. He holds degrees in journalism and management from the University of Minnesota and has won journalism awards from the Society of Professional Journalists, American Society of Business Publication Editors, and Trade, Association, Business Publications International. Connect with him on LinkedIn or by email at [email protected].